S&P 500   3,898.42 (+2.29%)
DOW   31,597.88 (+2.15%)
QQQ   321.28 (+2.27%)
AAPL   125.96 (+3.88%)
MSFT   236.43 (+1.74%)
FB   260.86 (+1.26%)
GOOGL   2,054.12 (+1.59%)
TSLA   711.93 (+5.39%)
AMZN   3,114.24 (+0.69%)
NVDA   548.11 (-0.09%)
BABA   239.87 (+0.89%)
CGC   35.02 (+6.93%)
GE   13.22 (+5.42%)
MU   94.46 (+3.20%)
NIO   49.74 (+8.65%)
AMD   85.28 (+0.91%)
T   28.22 (+1.18%)
F   12.05 (+2.99%)
ACB   11.31 (+7.51%)
DIS   195.10 (+3.21%)
BA   224.42 (+5.85%)
NFLX   550.07 (+2.08%)
BAC   35.63 (+2.65%)
S&P 500   3,898.42 (+2.29%)
DOW   31,597.88 (+2.15%)
QQQ   321.28 (+2.27%)
AAPL   125.96 (+3.88%)
MSFT   236.43 (+1.74%)
FB   260.86 (+1.26%)
GOOGL   2,054.12 (+1.59%)
TSLA   711.93 (+5.39%)
AMZN   3,114.24 (+0.69%)
NVDA   548.11 (-0.09%)
BABA   239.87 (+0.89%)
CGC   35.02 (+6.93%)
GE   13.22 (+5.42%)
MU   94.46 (+3.20%)
NIO   49.74 (+8.65%)
AMD   85.28 (+0.91%)
T   28.22 (+1.18%)
F   12.05 (+2.99%)
ACB   11.31 (+7.51%)
DIS   195.10 (+3.21%)
BA   224.42 (+5.85%)
NFLX   550.07 (+2.08%)
BAC   35.63 (+2.65%)
S&P 500   3,898.42 (+2.29%)
DOW   31,597.88 (+2.15%)
QQQ   321.28 (+2.27%)
AAPL   125.96 (+3.88%)
MSFT   236.43 (+1.74%)
FB   260.86 (+1.26%)
GOOGL   2,054.12 (+1.59%)
TSLA   711.93 (+5.39%)
AMZN   3,114.24 (+0.69%)
NVDA   548.11 (-0.09%)
BABA   239.87 (+0.89%)
CGC   35.02 (+6.93%)
GE   13.22 (+5.42%)
MU   94.46 (+3.20%)
NIO   49.74 (+8.65%)
AMD   85.28 (+0.91%)
T   28.22 (+1.18%)
F   12.05 (+2.99%)
ACB   11.31 (+7.51%)
DIS   195.10 (+3.21%)
BA   224.42 (+5.85%)
NFLX   550.07 (+2.08%)
BAC   35.63 (+2.65%)
S&P 500   3,898.42 (+2.29%)
DOW   31,597.88 (+2.15%)
QQQ   321.28 (+2.27%)
AAPL   125.96 (+3.88%)
MSFT   236.43 (+1.74%)
FB   260.86 (+1.26%)
GOOGL   2,054.12 (+1.59%)
TSLA   711.93 (+5.39%)
AMZN   3,114.24 (+0.69%)
NVDA   548.11 (-0.09%)
BABA   239.87 (+0.89%)
CGC   35.02 (+6.93%)
GE   13.22 (+5.42%)
MU   94.46 (+3.20%)
NIO   49.74 (+8.65%)
AMD   85.28 (+0.91%)
T   28.22 (+1.18%)
F   12.05 (+2.99%)
ACB   11.31 (+7.51%)
DIS   195.10 (+3.21%)
BA   224.42 (+5.85%)
NFLX   550.07 (+2.08%)
BAC   35.63 (+2.65%)
Log in
NASDAQ:TRIB

Trinity Biotech Stock Forecast, Price & News

$5.72
+0.36 (+6.72 %)
(As of 03/1/2021 11:00 AM ET)
Add
Compare
Today's Range
$5.56
Now: $5.72
$5.80
50-Day Range
$3.83
MA: $5.10
$6.64
52-Week Range
$0.56
Now: $5.72
$6.82
Volume1,820 shs
Average Volume605,568 shs
Market Capitalization$137.51 million
P/E RatioN/A
Dividend YieldN/A
Beta1.91
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.
Trinity Biotech logo

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRIB
CUSIPN/A
Phone353-1276-9800
Employees579
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.43 million
Cash Flow$0.05 per share
Book Value$0.20 per share

Profitability

Net Income$-28,910,000.00

Miscellaneous

Market Cap$137.51 million
Next Earnings Date3/30/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

0.46 out of 5 stars

Medical Sector

1607th out of 1,962 stocks

Diagnostic Substances Industry

29th out of 32 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$5.72
+0.36 (+6.72 %)
(As of 03/1/2021 11:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TRIB News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Trinity Biotech (NASDAQ:TRIB) Frequently Asked Questions

What stocks does MarketBeat like better than Trinity Biotech?

Wall Street analysts have given Trinity Biotech a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Trinity Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Trinity Biotech?

Trinity Biotech saw a decrease in short interest in January. As of January 15th, there was short interest totaling 127,000 shares, a decrease of 15.3% from the December 31st total of 150,000 shares. Based on an average daily volume of 326,300 shares, the short-interest ratio is currently 0.4 days.
View Trinity Biotech's Short Interest
.

When is Trinity Biotech's next earnings date?

Trinity Biotech is scheduled to release its next quarterly earnings announcement on Tuesday, March 30th 2021.
View our earnings forecast for Trinity Biotech
.

How were Trinity Biotech's earnings last quarter?

Trinity Biotech plc (NASDAQ:TRIB) announced its quarterly earnings data on Monday, November, 16th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.10 by $0.22. The company earned $32.01 million during the quarter. Trinity Biotech had a negative net margin of 21.75% and a positive trailing twelve-month return on equity of 277.50%.
View Trinity Biotech's earnings history
.

How has Trinity Biotech's stock price been impacted by COVID-19 (Coronavirus)?

Trinity Biotech's stock was trading at $1.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TRIB stock has increased by 367.8% and is now trading at $5.66.
View which stocks have been most impacted by COVID-19
.

Who are Trinity Biotech's key executives?

Trinity Biotech's management team includes the following people:
  • Mr. Ronan O'Caoimh, Chairman & CEO (Age 65, Pay $425k)
  • Dr. James Walsh, Exec. Director (Age 63)
  • Mr. John Gillard, CFO & Director

What is Ronan O'Caoimh's approval rating as Trinity Biotech's CEO?

20 employees have rated Trinity Biotech CEO Ronan O'Caoimh on Glassdoor.com. Ronan O'Caoimh has an approval rating of 8% among Trinity Biotech's employees. This puts Ronan O'Caoimh in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Trinity Biotech's key competitors?

What other stocks do shareholders of Trinity Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trinity Biotech investors own include Gilead Sciences (GILD), Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Netflix (NFLX), Pfizer (PFE), QUALCOMM (QCOM), Energy Transfer (ET) and Exxon Mobil (XOM).

What is Trinity Biotech's stock symbol?

Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."

Who are Trinity Biotech's major shareholders?

Trinity Biotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (7.93%), Hunter Associates Investment Management LLC (7.00%), Stonehill Capital Management LLC (4.13%), Navellier & Associates Inc (0.27%), Wealthsource Partners LLC (0.12%) and Virtu Financial LLC (0.12%).

Which institutional investors are selling Trinity Biotech stock?

TRIB stock was sold by a variety of institutional investors in the last quarter, including Stonehill Capital Management LLC, and Hunter Associates Investment Management LLC.

Which institutional investors are buying Trinity Biotech stock?

TRIB stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Navellier & Associates Inc, Mackenzie Financial Corp, Virtu Financial LLC, and Wealthsource Partners LLC.

How do I buy shares of Trinity Biotech?

Shares of TRIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trinity Biotech's stock price today?

One share of TRIB stock can currently be purchased for approximately $5.66.

How much money does Trinity Biotech make?

Trinity Biotech has a market capitalization of $136.07 million and generates $90.43 million in revenue each year.

How many employees does Trinity Biotech have?

Trinity Biotech employs 579 workers across the globe.

What is Trinity Biotech's official website?

The official website for Trinity Biotech is www.trinitybiotech.com.

Where are Trinity Biotech's headquarters?

Trinity Biotech is headquartered at IDA BUSINESS PARK BRAY, WICKLOW L2, .

How can I contact Trinity Biotech?

Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The company can be reached via phone at 353-1276-9800 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.